Fig. 7

Targeting LINC00930 and PFKFB3 in combination with radiotherapy induces tumor regression. a Schematic view of ASO targets on LINC0930 mRNA. b Relative expression of LINC00930 48 h after ASO transfection were determined by qRT-PCR. c qRT-PCR showed LINC00930 expression after ASOs delivery without transfect reagents. ASO were added into 5–8 cells at the concentration as indicated. After 48 h, RNA was extracted, and qRT-PCR was performed. d Cell viability was measured by CCK-8 assay afer irradiation of NPC cells treated with ASO LIN00930 or (and) PFK15. IR, Irradiation. e Schematic view of IR, ASO LINC00930 or (and) PFK15 treatment in CNE2-CDX and NPC-PDX xenograft model. CDX, cell-derived xenograft; PDX, patient-derived xenograft. f and g Statistical analysis of tumor volume in the CNE2-CDX, PDX-1, and PDX-2 models. IR, Irradiation. h Graphical abstract showing that the lncRNA LINC00930 promotes tumor glycolysis and cell proliferation by epigenetically upregulating PFKFB3. The p-value in b & c was determined by a two-tailed unpaired Student’s t test. The p-value in d, f & g was determined by one-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test, no adjustments were made for multiple comparisons. * p < 0.05; ** p < 0.01; *** p < 0.001